Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-05-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于收到上海证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a company responding to an inquiry letter from the Shanghai Stock Exchange regarding the company's 2017 Annual Report. The content focuses on detailed questions about financial performance, goodwill impairment, business operations, and investment activities related to the 2017 Annual Report. The document does not contain the actual annual report or financial statements but is a regulatory inquiry and the company's commitment to respond and disclose further information. The document length is 3289 characters, which is relatively short and consistent with an announcement rather than a full report. It explicitly states that the company will disclose the inquiry response and revise the periodic report accordingly. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement related to the annual report, not the report itself.
2018-05-11 Chinese
关于召开2017年年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement about the convening of the 2017 Annual General Meeting (AGM) of the company, including the date, voting methods, meeting agenda, and instructions for shareholders. It references the 2017 Annual Report and other reports to be discussed at the meeting but does not contain the reports themselves. The document is relatively short (3562 characters) and serves as a notice or reminder for the AGM rather than the actual report or voting results. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM.
2018-05-11 Chinese
2017年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is a detailed set of materials for the 2017 Annual General Meeting (AGM) of 中源协和细胞基因工程股份有限公司, dated May 16, 2018. It includes the meeting agenda, voting procedures, and multiple detailed reports such as the 2017 Annual Report, Board of Directors' work report, Supervisory Board report, financial statements, budget report, profit distribution proposal, auditor appointment, asset impairment provisions, and a subsidiary equity transfer proposal. The content is comprehensive and intended for discussion and approval at the AGM. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or a brief summary. Therefore, the correct classification is AGM-R with high confidence.
2018-05-07 Chinese
关于子公司和泽生物科技有限公司转让北京三有利和泽生物科技有限公司15.18%股权的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the transfer of equity shares of a subsidiary company and related investment activities. It includes information about the transaction parties, shareholding changes, financial data of the target company, reasons for the transaction, and risk disclosures. The document is not a full financial report, audit report, or earnings release. It is a formal announcement about a capital transaction involving share transfer and capital increase. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2018-05-04 Chinese
关于对上海证券交易所问询函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from 中源协和细胞基因工程股份有限公司 responding to an inquiry from the Shanghai Stock Exchange regarding multiple equity transactions involving subsidiaries and associated companies. It includes extensive explanations of accounting treatments, investment income recognition, compliance with accounting standards, auditor opinions, and detailed disclosures about the transactions, counterparties, and related risks. The document is not a full annual or interim financial report but rather a regulatory disclosure addressing specific questions about equity transactions and their accounting implications. It contains no full financial statements or comprehensive financial performance data but focuses on clarifications and compliance with accounting standards related to these transactions. Given the nature of the document as a regulatory response to an exchange inquiry and detailed disclosure of transaction and accounting matters, it fits best under Regulatory Filings (RNS).
2018-05-04 Chinese
瑞华会计师事务所关于上海证券交易所《关于对中源协和细胞基因工程股份有限公司出售下属公司股权并放弃增资事项的问询函》的回复
Regulatory Filings
2018-05-04 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.